TC BioPharm (Holdings) plc - Warrants (TCBPW)

0.0080Last Price

-0.0017 (-17.53%)Change

TC BioPharm Doses First 3 Patients in Phase 2b Clinical Trial of Lead Compound, OmnImmune®, To Treat Acute Myeloid Leukemiabenzinga.com

TC Biopharm (NASDAQ: TCBP) (NASDAQ: TCBPW) recently announced the dosing of its first three patients within its Phase 2b clinical trial of OmnImmune®,

Via Benzinga · November 22, 2022